Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CRIS, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| chondrocyte-alginate gel suspension | Vesicoureteral Reflux | Phase 3 · NCT00004487 | Unknown |
| Emavusertib (CA-4948) | Myelodysplastic Syndromes | Phase 2 · NCT05178342 | Terminated |
| Zanubrutinib | Chronic Lymphocytic Leukemia | Phase 2 · NCT07271667 | Recruiting |
| Fimepinostat (CUDC-907) | Relapsed and/or Refractory Diffuse Large B-cell Ly | Phase 2 · NCT02674750 | Completed |
| Smac Mimetic GDC-0917 | Lymphoma | Phase 1 · NCT01908413 | Terminated |
| HDAC/EGFR/HER2 Inhibitor CUDC-101 | Head and Neck Cancer | Phase 1 · NCT01384799 | Completed |
| mFOLFOX7 | Gastric Cancer | Phase 1 · NCT05187182 | Recruiting |
| Onvatilimab (CI-8993) | Solid Tumor | Phase 1 · NCT04475523 | Completed |
| Cenopodlin (CA-170) | Advanced Solid Tumors or Lymphomas | Phase 1 · NCT02812875 | Completed |
Also used in these trials (approved or third-party drugs, not CRIS's own candidates): Venetoclax, Ibrutinib, Durvalumab, Gemcitabine Hydrochloride, Cisplatin, Nivolumab, Pembrolizumab, Rituximab, Trastuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CRIS holds $5.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.3M/quarter from operations, an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRIS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRIS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →